BBa_K1179070
BBa_K1179070 Version 1 (Component)
CMV promoter

BBa_K300980
BBa_K300980 Version 1 (Component)
BBa_K300001 construction intermediate (provided by Mr Gene)

BBa_K2044000
BBa_K2044000 Version 1 (Component)
Based on our project, <2-6-8> is the optimal pathway scheme from Site No. 2 to Site No. 8

BBa_M11085
BBa_M11085 Version 1 (Component)
E coli outer membrane protein C (ompC) with BamHI RE site for insertion of gene to be expressed on o

BBa_K300983
BBa_K300983 Version 1 (Component)
BBa_K300000 construction intermediate (provided by Mr Gene)

BBa_K1150015
BBa_K1150015 Version 1 (Component)
CMV promoter

BBa_K2044010
BBa_K2044010 Version 1 (Component)
Based on our project, <5,7> is the direct pathway from Site No.5to Site No.7 in the map we design.

BBa_J52648
BBa_J52648 Version 1 (Component)
CMV+GFP

BBa_M36689
BBa_M36689 Version 1 (Component)
HSE 2x Promoter + Bxb1 Recombinase w/ NLS + SV40 Terminator + attB site + CMV Reverse + attP site

BBa_S04224
BBa_S04224 Version 1 (Component)
CAT+TT on pSB1AK3

BBa_K2044006
BBa_K2044006 Version 1 (Component)
Based on our project,<3,6> is the direct pathway from Site No.3 to Site No.6 in the map we design.

BBa_K2044004
BBa_K2044004 Version 1 (Component)
Based on our project, <2,4> is the direct pathway from Site No.2 to Site No.4 in the map we design.

BBa_K2044009
BBa_K2044009 Version 1 (Component)
Based on our project, <4,8> is the direct pathway from Site No.4 to Site No.8 in the map we design.

BBa_K2044014
BBa_K2044014 Version 1 (Component)
Based on our project, <1,4> is the direct pathway from Site No.1 to Site No.4 in the map we design.

BBa_K2044007
BBa_K2044007 Version 1 (Component)
Based on our project, <4,5> is the direct pathway from Site No.4 to Site No.5 in the map we design.

BBa_K2044013
BBa_K2044013 Version 1 (Component)
Based on our project,<7,8> is the direct pathway from Site No.7 to Site No.8 in the map we design.

BBa_K2044008
BBa_K2044008 Version 1 (Component)
Based on our project, <4,6> is the direct pathway from Site No.4 to Site No.6 in the map we design.

BBa_K2044003
BBa_K2044003 Version 1 (Component)
Based on our project, <2,3> is the direct pathway from Site No.2 to Site No.3 in the map we design.

BBa_K2044002
BBa_K2044002 Version 1 (Component)
Based on our project, <2,1> is the direct pathway from Site No.2 to Site No.1 in the map we design.

BBa_K2044005
BBa_K2044005 Version 1 (Component)
Based on our project, <2,6> is the direct pathway from Site No.2 to Site No.6 in the map we design.

BBa_K2044012
BBa_K2044012 Version 1 (Component)
Based on our project, <6,8> is the direct pathway from Site No.6 to Site No.8 in the map we design.

BBa_K2044011
BBa_K2044011 Version 1 (Component)
Based on our project,<6,4> is the direct pathway from Site No.6 to Site No.4 in the map we design.

CMV promot
BBa_K157042 Version 1 (Component)
Eukaryotic CMV promoter

BBa_K125000
BBa_K125000 Version 1 (Component)
Broad host range BioBrick plasmid derived from pRL1383a with low to medium copy number

BBa_K133175
BBa_K133175 Version 1 (Component)
CMV-SS-gyrEC

BBa_K133172
BBa_K133172 Version 1 (Component)
CMV-SS-gyrHP

BBa_M36561
BBa_M36561 Version 1 (Component)
This terminator is a general terminator of transcription. It forms a stem loop which stops transcrip

BBa_J04795
BBa_J04795 Version 1 (Component)
Riboswitch designed to turn "ON" a protein

BBa_I763003
BBa_I763003 Version 1 (Component)
GFP coding device switched on by IPTG

placIQ RBS
BBa_K193604 Version 1 (Component)
GFP behind a constitutive promoter (placIQ) on pSB4A5

BBa_K133020
BBa_K133020 Version 1 (Component)
CMV-CF213-multiHP-CF215-RGD-Histop (term.)

BBa_K133023
BBa_K133023 Version 1 (Component)
CMV-ss-CF213-multiHP-CF215-RGD-Histop (term)

BBa_K165100
BBa_K165100 Version 1 (Component)
Gli1 bs + LexA bs + mCYC + LexA repressor (mCherryx2 tagged) on pRS304*

BBa_K1222004
BBa_K1222004 Version 1 (Component)
pCam(T7 promoter+lac operator+CamR antisense 2+T7 terminator)

BBa_K165101
BBa_K165101 Version 1 (Component)
Zif268-HIV bs + LexA bs + mCYC + Zif268-HIV repressor (mCherryx2 tagged) on pRS304*

SEGA
SEGA_collection Version 1 (Collection)
In the Standardized Genome Architecture (SEGA), genomic integration of DNA fragments is enabled by λ-Red recombineering and so-called landing pads that are a common concept in synthetic biology and typically contain features that i) enable insertion of additional genetic elements and ii) provide well-characterized functional parts such as promoters and genes, and iii) provides insulation against genome context-dependent effects. The SEGA landing pads allow for reusable homology regions and time-efficient construction of parallel genetic designs with a minimal number of reagents and handling steps. SEGA bricks, typically synthetic DNA or PCR fragments, are integrated on the genome simply by combining the two reagents (i.e. competent cells and DNA), followed by incubation steps, and successful recombinants are identified by visual inspection on agar plates. The design of the SEGA standard was heavily influenced by the Standard European Vector Architecture (SEVA). SEGA landing pads typically hosts two major genetic “control elements” that influence gene expression on the transcriptional (C1), and translational (C2) level. Furthermore, landing pads contain gadgets such as selection and counterselection markers.

Intein_assisted_Bisection_Mapping
Intein_assisted_Bisection_Mapping_collection Version 1 (Collection)
Split inteins are powerful tools for seamless ligation of synthetic split proteins. Yet, their use remains limited because the already intricate split site identification problem is often complicated by the requirement of extein junction sequences. To address this, we augmented a mini-Mu transposon-based screening approach and devised the intein-assisted bisection mapping (IBM) method. IBM robustly revealed clusters of split sites on five proteins, converting them into AND or NAND logic gates. We further showed that the use of inteins expands functional sequence space for splitting a protein. We also demonstrated the utility of our approach over rational inference of split sites from secondary structure alignment of homologous proteins. Furthermore, the intein inserted at an identified site could be engineered by the transposon again to become partially chemically inducible, and to some extent enabled post-translational tuning on host protein function. Our work offers a generalizable and systematic route towards creating split protein-intein fusions and conditional inteins for protein activity control.